The dementia‐free survival time was defined as the time from the day of enrolment to a diagnosis of dementia. Statins. I have read and accept the Wiley Online Library Terms and Conditions of UseCochrane review on ‘statins for the treatment of dementia’Global prevalence of dementia: a Delphi consensus studyCholesterol and Alzheimer's disease: is there a link?Amyloid‐beta oligomers set fire to inflammasomes and induce Alzheimer's pathologyInteractions of apolipoprotein e genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case‐control studyApolipoprotein e epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late‐life Alzheimer diseaseRelation of plasma lipids to Alzheimer disease and vascular dementiaStatins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity.

The trial will help determine whether a statin can help prevent dementia and disability in this age group, as well as heart attacks and other cardiovascular-related deaths, while not increasing risks of adverse health outcomes. Statins appear to prevent physical disability and cardiovascular disease in healthy community-dwelling adults ≥70 years old, but do not prolong disability-free survival or avoid the risk of death or dementia, according to a study published June 29 in the Journal of the American College of Cardiology.. Independent of traditional risk factors, there was a decrease in newly diagnosed cases of dementia in elderly patients who had received a high total or daily dose of statins. Wagstaff The strengths of this study include its population‐based, nationwide design with the capture of all validated cases of dementia occurring amongst the elderly population of the entire country over a 12‐year period. Kaplan–Meier curves showing the development of dementia amongst patients taking different doses of statins as total equivalent dose (a) and mean equivalent daily dose (b). Indeed, studies finding a negative correlation of cholesterol level with dementia risk were principally conducted in elderly patients, whereas studies finding a positive correlation tended to include younger patients . The investigators will enroll 20,000 participants without signs of heart disease but who may be frail, take multiple medications and have mild cognitive impairment.

atorvastatin and rosuvastatin) seemed to have a greater ability to prevent dementia.None of the authors has any conflict of interest to declare.Please check your email for instructions on resetting your password. Previous studies have shown that not only the decrease in plasma cholesterol but also the pleiotropic (e.g. A meta-analysis looking at observational studies investigating statins and the risk of dementia looked at data from 11 studies, involving over 23,000 participants, who had been taking statins for between 3 and nearly 25 years on average. transient ischaemic accident, ischaemic stroke and haemorrhagic stroke; ICD‐9‐CM codes: 435.X, 434.X and 430.X–432.X), or chronic kidney disease (ICD‐9‐CM codes: 585.X–588.X).Propensity score (PS) matching is a method used to balance observed covariates in two treatment groups Comparisons of baseline characteristics (categorical covariates) including the use of different statins were made using the chi‐squared test between subjects with and without dementia. The study population was then divided into tertiles according to both the use of particular statins and the daily statin equivalent dose.

There were no statistically significant differences in age, sex, comorbidity, medication use (except statins) and other clinical variables between the two groups (Table We excluded patients who had used more than one type of statin and compared the effect of different statins by Cox proportional hazard models (Table The dose–response effect of the total accumulated statin dose in different patient subgroups is shown in Table To the best of our knowledge, this was the first large‐scale, nationwide study to examine the effect of different statins on newly diagnosed dementia in an elderly population. The main exposure of interest was statin therapy, identified from prescription claims. Patients with established dementia before the start of treatment were excluded.

Data on other prescribed medications including angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, oral hypoglycaemic agents and insulin were also collected.